Modified HIV-1 gp41 Cyclic Peptides for Antibody Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunoassays for detecting HIV-1 M antibodies have limitations in sensitivity and specificity, failing to detect all seroconversion samples, particularly in early stages of infection, which is critical for preventing transmission during blood transfusions.
Innovation Solution
Development of novel cyclic peptides derived from the HIV-1 virus gp41, with specific amino acid modifications to enhance solubility and sensitivity, allowing for the detection of all seroconversion samples by forming antigen-antibody complexes and using these peptides in diagnostic kits and assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional immunoassays use viral lysate or recombinant antigens for detecting anti-HIV-1 M antibodies, then the assay can detect most infections, but the sensitivity is insufficient to detect all seroconversion samples particularly in early stages
Solution Approach 1:
The patent segments the gp41 envelope glycoprotein into specific peptide regions (amino acids 584-602 and 611-630) to identify and utilize immunodominant epitopes that are more effective at detecting early seroconversion antibodies. This segmentation allows the assay to focus on the most immunogenic portions of the virus rather than using whole viral lysate or large recombinant proteins.
Solution Approach 2:
The patent modifies the peptide sequence by introducing specific amino acid substitutions (such as L69F, L69M, L69V, L69I, L69P, L69A, L69G, L69S, L69T, L69N, L69D, L69E, L69Q, L69R, L69K, L69H, L69C, L69W, L69Y, L69X, L69Z) to enhance the immunoreactivity and stability of the epitopes, thereby improving detection sensitivity without sacrificing reliability.
2Measurement precision
If the peptide sequence is modified to enhance immunoreactivity, then the detection sensitivity improves, but the peptide solubility and stability may deteriorate
Solution Approach 1:
The patent carefully selects amino acid substitutions that enhance immunoreactivity while maintaining or improving peptide solubility and stability. For example, substituting hydrophobic residues with hydrophilic ones or introducing charged residues can improve solubility, while strategic substitutions can enhance binding affinity to antibodies.
Solution Approach 2:
The patent creates composite peptide structures by combining multiple epitopic regions within a single peptide molecule, linked by flexible spacers. This composite approach allows the peptide to present multiple antigenic determinants simultaneously, enhancing detection sensitivity while the flexible linkers maintain solubility and structural stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified peptides significantly improve the detection of HIV-1 M antibodies, enabling earlier detection of seroconversions and increasing sensitivity, thereby reducing the risk of transmitting HIV-1 M through blood transfusions.
Implementation Method 1
allowing for the detection of all seroconversion samples by forming antigen-antibody complexes
Data Source
AI summary
The invention involves a synthetic peptide derived from HIV-1 virus gp41 having sequencewhere X615 is F or G, a method of preparing the synthetic peptide, a composition and a kit containing the synthetic peptide, and use of the synthetic peptide in immunoassays for the detection of infections caused by HIV-1 viruses.